Results 21 to 30 of about 249 (106)

Effectiveness and Safety of the Novel Selective Urate Reabsorption Inhibitor Dotinurad After Switching from Febuxostat in Patients with Stage B/C Heart Failure [PDF]

Drugs - Real World Outcomes
Background Hyperuricemia is a common comorbidity in patients with cardiovascular diseases and chronic kidney disease, often requiring long-term urate-lowering therapy.
Tsutomu Murakami, Yuki Watanabe, Norihito Nakamura, Shigemitsu Tanaka, Yuji Ikari   +4 more
doaj   +2 more sources

Changes in uric acid levels and estimated glomerular filtration rate slope after treatment with dotinurad in patients with hyperuricemia [PDF]

BMC Nephrology
Background Hyperuricemia is a recognized risk factor for chronic kidney disease (CKD). Dotinurad, a novel selective urate reabsorption inhibitor, effectively lowers uric acid (UA) levels.
Tatsuya Mizoguchi, Kosuke Hayashi, Yoshiro Tsuruta, Yu Kawada, Masashi Yokoi, Sayuri Yamabe, Kento Mori, Kyoko Matsui, Tsuyoshi Ito, Shuichi Kitada, Toshihiko Goto, Yoshihiro Seo   +11 more
doaj   +2 more sources

Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies [PDF]

Frontiers in Endocrinology
Hyperuricemia is a metabolic disease caused by purine metabolism disorders. In recent years, its incidence has been increasing year by year and showing a trend of rejuvenation.
Xinze Li, Zilong Chen, Yanzhao Zhang, Chunyang Fan, Lulu Chen, Xiangman Xu, Jianying Chang, Wei Qiang, Hongwei Jiang, Chuanxin Liu   +9 more
doaj   +2 more sources

Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease [PDF]

BMC Nephrology
Background In this study, we aimed to clarify the beneficial effects of urate-lowering treatment with the novel agent dotinurad on renal function in patients with chronic kidney disease (CKD) and hyperuricemia (HUA). Methods Thirty-five patients with CKD
Hoichi Amano, Seiji Kobayashi, Hiroyuki Terawaki   +2 more
doaj   +2 more sources

The Human Urate Transportosome: Evolutionary Dynamics, Molecular Mechanisms, and Pharmacogenetic Perspectives [PDF]

Medical Sciences
Background: The hominoid loss of urate oxidase (uricase) represents a classic evolutionary trade-off, shifting uric acid (UA) from a metabolic waste product to a potent physiological modulator.
Lilya U. Dzhemileva, Vladimir A. D’yakonov, Sergey N. Marshala, Elza Khusnutdinova, Andrey A. Deviatkin, German A. Shipulin   +5 more
doaj   +2 more sources

Real-world use of dotinurad and one-year prescription presence by kidney function in older adults

Scientific Reports
Evidence on dotinurad, a selective urate transporter 1 inhibitor, in older adults with reduced kidney function is limited. We conducted a retrospective cohort study using the Japan Medical Data Center elderly claims database from April 2021 to February ...
Ryosuke Saiki, Masaki Tanabe, Tomohiro Murata, Daisuke Yamasaki, Shiho Ito, Kan Katayama, Kaoru Dohi   +6 more
doaj   +2 more sources

Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China. [PDF]

Arthritis Rheumatol
Objective Dotinurad is a selective urate reabsorption inhibitor that reduces serum urate levels. We compared the efficacy and safety of dotinurad with febuxostat in Chinese patients with gout. Methods This phase 3, multicenter, randomized, double‐blind, parallel‐group study randomly allocated (1:1) eligible patients with gout to receive oral dotinurad ...
Sun J, Wang Y, Cheng Y, Guo D, Hu J, Liu D, Gao Z, Li C, Lu Y, Kong X, Liu Y, Jiang Z, Yi B, Zhang H, Xu B, Yu S, Kokan R, Ishikawa K, Kawakatsu M, Zhang Z.   +19 more
europepmc   +2 more sources

Molecular Mechanisms and Clinical Evidence Supporting the Four Pillars of Therapy in Diabetic Kidney Disease: Emerging Therapeutic Perspectives. [PDF]

Int J Mol Sci
Yanai H, Adachi H, Hakoshima M, Katsuyama H.   +3 more
europepmc   +2 more sources

URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice

Molecular Metabolism, 2022
Objective: Accumulating evidence indicates that high uric acid (UA) is strongly associated with obesity and metabolic syndrome and drives the development of nonalcoholic fatty liver disease (NAFLD) and insulin resistance.
Yoshiro Tanaka, Tomohisa Nagoshi, Hirotake Takahashi, Yuhei Oi, Akira Yoshii, Haruka Kimura, Keiichi Ito, Yusuke Kashiwagi, Toshikazu D. Tanaka, Michihiro Yoshimura   +9 more
doaj   +1 more source

The Concise Guide to PHARMACOLOGY 2023/24: Transporters

British Journal of Pharmacology, Volume 180, Issue S2, Page S374-S469, October 2023., 2023
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and over 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links
Stephen P. H. Alexander, Doriano Fabbro, Eamonn Kelly, Alistair A. Mathie, John A. Peters, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Jamie A. Davies, Laura Amarosi, Catriona M. H. Anderson, Philip M. Beart, Stefan Broer, Paul A. Dawson, Gergely Gyimesi, Bruno Hagenbuch, James R. Hammond, Jules C. Hancox, Michal Hershfinkel, Ken‐ichi Inui, Yoshikatsu Kanai, Stephan Kemp, Edmund R. S. Kunji, Gavin Stewart, Sotiria Tavoulari, David T. Thwaites, Tiziano Verri   +27 more
wiley   +1 more source